<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316898</url>
  </required_header>
  <id_info>
    <org_study_id>3142-101-001</org_study_id>
    <nct_id>NCT03316898</nct_id>
  </id_info>
  <brief_title>A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron
      Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in
      patients with mild to moderate Alzheimer's Disease on a stable dose of 10 mg donepezil with
      or without memantine standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2018</start_date>
  <completion_date type="Anticipated">November 4, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR) for Whole Brain, Hippocampal and Dorsolateral Prefrontal Cortices</measure>
    <time_frame>Baseline (Day -3 to Day -1) to Day 28</time_frame>
    <description>The effects of AGN-242071 on brain metabolic activity or glucose metabolism will be determined using the FDG-PET scan by reporting results as SUVR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Treatment-Emergent Adverse Events (TEAE)</measure>
    <time_frame>Day 1 to Day 35</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE that occurs during the treatment period will be considered a TEAE if it was not present before the first dose or if it was present but increased in severity during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Changes from Baseline in Clinically Significant Clinical Laboratory Values</measure>
    <time_frame>Baseline (Day -3 to Day -1) to Day 35</time_frame>
    <description>Clinical laboratory safety tests include Chemistry, Hematology and Urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Changes from Baseline in Clinically Significant Vital Signs</measure>
    <time_frame>Baseline (Day -3 to Day -1) to Day 35</time_frame>
    <description>Vital signs include systolic and diastolic blood pressure, pulse rate, weight, respiration rate, and temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Changes from Baseline in Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline (Day -3 to Day -1) to Day 35</time_frame>
    <description>A standard 12-lead ECG will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who have Suicidal Ideation or Behaviours as determined by Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline (Day 1) to Day 35</time_frame>
    <description>The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior since the last visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of AGN-242071</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Clearance will be determined utilizing a population pharmacokinetic (PK) approach implemented in non-linear mixed effects modeling (NONMEM®) software.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution of AGN-242071</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Volume of Distribution will be determined utilizing a population PK approach implemented in NONMEM® software.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Plasma concentration for AGN-242071</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC: Area Under the Curve for AGN-242071</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo capsules once daily for 28 Days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-242071 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-242071 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-242071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-242071 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-24071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 10 followed by AGN-242071 25 mg total dose (one 5 mg and one 20 mg capsules) on Days 11 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-242071</intervention_name>
    <description>AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.</description>
    <arm_group_label>AGN-242071 5 mg</arm_group_label>
    <arm_group_label>AGN-242071 15 mg</arm_group_label>
    <arm_group_label>AGN-242071 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>AGN-242071 5 mg</arm_group_label>
    <arm_group_label>AGN-242071 15 mg</arm_group_label>
    <arm_group_label>AGN-242071 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil 10 mg as prescribed by the physician as per standard of care.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>AGN-242071 5 mg</arm_group_label>
    <arm_group_label>AGN-242071 15 mg</arm_group_label>
    <arm_group_label>AGN-242071 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Memantine as prescribed by the physician as per standard of care.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>AGN-242071 5 mg</arm_group_label>
    <arm_group_label>AGN-242071 15 mg</arm_group_label>
    <arm_group_label>AGN-242071 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic evidence of probable Alzheimer's Disease (AD) per the 2011 National
             Institutes of Aging-Alzheimer's Association (NIA-AA) criteria

          -  Participants receiving donepezil at a stable dose of 10 mg daily with or without
             stable dose memantine for at least 6 weeks prior to the screening visit.

        Exclusion Criteria:

          -  Participants with illness apart from AD that could contribute to cognitive dysfunction

          -  History of clinically significant suicidal ideation within the past 6 months

          -  Thyroid disease unless the participant is euthyroid and stable on treatment for at
             least 3 months prior to screening

          -  Participants with a personal or family history of congenital long QT syndrome or
             sudden death

          -  Clinically significant cardiovascular disease in the past 6 months prior to screening

          -  Participants with signs and symptoms of peripheral vascular disease (PVD)

          -  A transient ischemic attack or other acute ischemic event affecting the brain, spinal
             cord, or peripheral circulation in the past 6 months prior to screening

          -  Any history of cerebrovascular accident or stroke

          -  Any history of a seizure disorder other than a single febrile seizure

          -  Pulmonary disease or evidence of clinically significant moderate or severe pulmonary
             symptoms

          -  History of cancer within the last 5 years

          -  Evidence or history of diabetes mellitus Type 1

          -  Any significant sensory (eg, moderate to severely impaired hearing or severely
             impaired vision) or hand movement difficulties that would prevent participants from
             completing the behavioral assessments of the study

          -  Treatment with cholinesterase inhibitors other than donepezil or other cholinomimetics
             within 12 weeks of the baseline visit

          -  Treatment with memantine not in combination with donepezil within 12 weeks of the
             baseline Visit

          -  Participants who have been on anticholinergic and/or antimuscarinic treatment
             including overactive bladder treatments, antihistamines, antipsychotics, and tricyclic
             antidepressants, within 12 weeks prior to the baseline visit

          -  Participants who have been on drugs that are strong inhibitors of CYP2D6 or CYP2C9
             (eg, quinidine, paroxetine, fluoxetine, terbinafine, bupropion), or that are moderate
             or strong inhibitors of CYP3A4 (eg, erythromycin, ketoconazole, rifampicin,
             fluconazole, carbamazepine) within 21 days prior to the baseline visit

          -  Participants who are taking any moderate or strong inducers of CYP3A4 (eg,
             carbamazepine, phenytoin, rifampin, modafinil, and herbal preparations containing St.
             John's wort) or strong inducers of CYP2C9 within 21 days prior to the baseline visit

          -  Participants who have been on other drugs that could affect cognition (eg,
             benzodiazepines or gamma-aminobutyric acid A (GABAA) receptor agonists used as
             anxiolytics, sedative-hypnotics) or over-the-counter (OTC) sleeping aids within 12
             weeks prior to the baseline visit

          -  Participants who have been on hormone replacement therapy, thyroid supplement, vitamin
             E, or vitamin B12 unless at a stable dose for 4 weeks before the baseline visit

          -  Use of an active Alzheimer's disease vaccine within 2 years prior to screening or
             monoclonal antibody for treatment of AD within 1 year prior to screening

          -  Positive test results for anti-human immunodeficiency virus (anti-HIV) type 1 and 2,
             hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (anti-HCV) at screening

          -  Positive test results for urine drug screen for methadone, cocaine,
             tetrahydrocannabinol, benzodiazepines, tricyclic antidepressants, barbiturates,
             phencyclidine, amphetamines, methamphetamine, and opiates at screening or baseline
             visit

          -  Participants with a body weight of less than 40 kg

          -  Consumption of food or drinks containing grapefruit juice, cranberry, pomegranate,
             star fruit, grapefruit, pomelos, exotic citrus fruits or Seville orange or of alcohol
             within 72 hours before administration of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitalee Tamhane, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>877‐277‐8566</phone>
    <email>IR-CTRegistration@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ATP Clinical Research</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>94105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Centers</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tibor Rubin VA Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

